Alison Lee - GeneReach Biotechnology Chief Officer

All Insiders . Taiwan . 
Stock . GeneReach Biotechnology . Stakeholders . Insider . Alison Lee
4171 Stock  TWD 28.90  0.20  0.70%   

Insider

Alison Lee is Chief Officer of GeneReach Biotechnology
Phone886 4 2463 9869
Webhttps://www.genereach.com

GeneReach Biotechnology Management Efficiency

The company has return on total asset (ROA) of 0.1319 % which means that it generated a profit of $0.1319 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3007 %, meaning that it generated $0.3007 on every $100 dollars invested by stockholders. GeneReach Biotechnology's management efficiency ratios could be used to measure how well GeneReach Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.
GeneReach Biotechnology has accumulated 217.39 M in total debt with debt to equity ratio (D/E) of 0.3, which may suggest the company is not taking enough advantage from borrowing. GeneReach Biotechnology has a current ratio of 5.11, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist GeneReach Biotechnology until it has trouble settling it off, either with new capital or with free cash flow. So, GeneReach Biotechnology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GeneReach Biotechnology sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GeneReach to invest in growth at high rates of return. When we think about GeneReach Biotechnology's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Jian ChenWiseChip Semiconductor
N/A
ShiaoYu BaoLeader Electronics
N/A
Allan YangAdvantech Co
N/A
Kam KooGiant Manufacturing Co
N/A
ShuYing WuCathay Financial Holding
N/A
ChingChi ChenKinko Optical Co
N/A
Judie HsuCathay Financial Holding
N/A
MingChiao LiangCathay Financial Holding
N/A
Liling WangCathay Financial Holding
N/A
ChingHsin YenGiant Manufacturing Co
N/A
Andrew BaoLeader Electronics
N/A
ChungYee PaoLeader Electronics
N/A
JianHsing WuCathay Financial Holding
N/A
ShuFen ChengCathay Financial Holding
N/A
ChungYi TengCathay Financial Holding
N/A
David SunCathay Financial Holding
59
LiangChang ChouKinko Optical Co
N/A
Grace LiaoAdvantech Co
N/A
ChenTung ChenGreat Taipei Gas
N/A
MingHo HsiungCathay Financial Holding
N/A
YuMei LeeCathay Financial Holding
N/A
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. GeneReach Biotechnology Corp. was founded in 2004 and is headquartered in Taichung, Taiwan. GENEREACH BIOTECHNOLOGY operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange. GeneReach Biotechnology (4171) is traded on Taiwan OTC Exchange in Taiwan and employs 16 people.

Management Performance

Return On Equity0.3
Return On Asset0.13

GeneReach Biotechnology Leadership Team

Elected by the shareholders, the GeneReach Biotechnology's board of directors comprises two types of representatives: GeneReach Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GeneReach. The board's role is to monitor GeneReach Biotechnology's management team and ensure that shareholders' interests are well served. GeneReach Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GeneReach Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
Alison Lee, Chief Officer
Grace Chang, Chief Officer
David Tsai, Chief Officer
Simon Chung, Chief Officer
Yuwen Huang, Deputy General Manager-Compliance & Production

GeneReach Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GeneReach Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.3
Return On Asset0.13
Profit Margin0.38 %
Operating Margin0.43 %
Current Valuation2.09 B
Shares Outstanding45.97 M
Shares Owned By Insiders34.96 %
Shares Owned By Institutions4.57 %
Price To Earning8.39 X
Price To Book2.37 X

Pair Trading with GeneReach Biotechnology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GeneReach Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GeneReach Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Moving together with GeneReach Stock

  0.784743 Oneness BiotechPairCorr
  0.886547 Medigen Vaccine BiologicsPairCorr
  0.914174 OBI PharmaPairCorr

Moving against GeneReach Stock

  0.912882B Cathay Financial HoldingPairCorr
  0.892891 CTBC Financial HoldingPairCorr
  0.842883 China DevelopmentPairCorr
  0.812881A Fubon Financial HoldingPairCorr
  0.812330 Taiwan SemiconductorPairCorr
The ability to find closely correlated positions to GeneReach Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GeneReach Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GeneReach Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GeneReach Biotechnology to buy it.
The correlation of GeneReach Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GeneReach Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GeneReach Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GeneReach Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for GeneReach Stock Analysis

When running GeneReach Biotechnology's price analysis, check to measure GeneReach Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneReach Biotechnology is operating at the current time. Most of GeneReach Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneReach Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneReach Biotechnology's price. Additionally, you may evaluate how the addition of GeneReach Biotechnology to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY